Matsuzaki Shinya, Matsushima Kazuhide, McIntyre Denise S, Song Bonnie B, Mandelbaum Rachel S, Hisa Tsuyoshi, Klar Maximilian, Muderspach Laila I, Wright Jason D, Matsuo Koji
Department of Gynecology, Osaka International Cancer Institute, Osaka, Japan.
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Sci Rep. 2025 May 2;15(1):15340. doi: 10.1038/s41598-025-99863-3.
In this nationwide cross-sectional study of 4,055,462 hospital admissions with a diagnosis of coronavirus disease 2019 (COVID-19) from April 2020 to December 2021 identified in the Agency of Healthcare Research and Quality's Healthcare Cost and Utilization Project National Inpatient Sample in the United States, a total of 489,390 (12.1%) patients experienced endotracheal intubation and mechanical ventilation, with the highest peak in August 2021 (48,735 endotracheal intubations and mechanical ventilation), followed by January 2021 (47,100 endotracheal intubations and mechanical ventilation) and December 2021 (43,835 endotracheal intubations and mechanical ventilation). During the 3-month long large surge from November 2020 to January 2021, a total of 104,750 endotracheal intubations and mechanical ventilation occurred among 1,069,874 COVID-19 admissions. Shock (adjusted-odds ratio 24.21, 95% confidence interval 23.93-24.49) and respiratory failure (adjusted-odds ratio 14.09, 95% confidence interval 13.80-14.38) were the two strongest factors associated with endotracheal intubation and mechanical ventilation. A total of 266,585 (6.6%) patients received non-invasive respiratory support alone without endotracheal intubation and mechanical ventilation during the study period with the highest peak in August 2021 (30,725 cases), followed by January 2021 (28,035 cases), and December 2021 (26,200 cases). The utilization of non-invasive respiratory support without endotracheal intubation and mechanical ventilation increased by nearly three-fold during the 21-month study period (adjusted-odds ratio for the fourth year-quarter of 2021 compared to the second year-quarter of 2020 2.94, 95% confidence interval 2.88-3.00). A total of 515,800 (12.7%) deaths occurred during COVID-19 hospitalization, with highest in the peak of multi-month lasting largest surge (January 2021, 56,775 deaths), followed by August 2021 (47,535 deaths) and December 2021 (46,880 deaths). Among those who deceased following endotracheal intubation and mechanical ventilation, the median time from admission to death was 14 days (interquartile range 7-21). COVID-19 admissions, respiratory intervention approach, and COVID-19 case fatality differed across the nine U.S. census divisions during the study period. In conclusion, these statistics may be useful to inform the national-level preparedness of global pandemic from respiratory illness in the future, possibly exceeding 48,000 endotracheal intubations and mechanical ventilation across the country in a month and 100,000 endotracheal intubations and mechanical ventilation in three months when encountering long-lasting surge with one-million admissions.
在这项全国性横断面研究中,从美国医疗保健研究与质量局的医疗成本和利用项目全国住院患者样本中,识别出2020年4月至2021年12月期间4,055,462例诊断为2019冠状病毒病(COVID-19)的住院病例,共有489,390例(12.1%)患者接受了气管插管和机械通气,2021年8月达到最高峰(48,735例气管插管和机械通气),其次是2021年1月(47,100例气管插管和机械通气)和2021年12月(43,835例气管插管和机械通气)。在2020年11月至2021年1月为期3个月的大幅激增期间,1,069,874例COVID-19住院病例中共有104,750例接受了气管插管和机械通气。休克(调整后的优势比为24.21,95%置信区间为23.93 - 24.49)和呼吸衰竭(调整后的优势比为14.09,95%置信区间为13.80 - 14.38)是与气管插管和机械通气相关的两个最强因素。在研究期间,共有266,585例(6.6%)患者仅接受了无创呼吸支持,未进行气管插管和机械通气,最高峰出现在2021年8月(30,725例),其次是2021年1月(28,035例)和2021年12月(26,200例)。在21个月的研究期间,未进行气管插管和机械通气的无创呼吸支持的使用率增加了近三倍(与2020年第二季度相比,2021年第四季度的调整后优势比为2.94,95%置信区间为2.88 - 3.00)。COVID-19住院期间共有515,800例(12.7%)死亡病例,在持续数月的最大激增高峰期(2021年1月,56,775例死亡)最高,其次是2021年8月(47,535例死亡)和2021年12月(46,880例死亡)。在接受气管插管和机械通气后死亡的患者中,从入院到死亡的中位时间为14天(四分位间距为7 - 21天)。在研究期间,美国九个人口普查分区的COVID-19住院病例、呼吸干预方法和COVID-19病死率各不相同。总之,这些统计数据可能有助于为未来全球呼吸道疾病大流行的国家级防范提供信息,在遇到持续百万例住院病例的长期激增时,可能一个月内在全国超过48,000例气管插管和机械通气病例,三个月内超过100,000例气管插管和机械通气病例。